

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 MAY 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item

PBAC Advice

Carbomer 974

The sponsor requested the delisting of Poly Gel[®] (carbomer 974) from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted the relatively low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.

Procaine benzylpenicillin

The sponsor requested the delisting of Cilicaine[®] (procaine benzylpenicillin) from the PBS.

The PBAC noted the low number of services in the last financial year. The PBAC considered that, while there are alternatives available on the PBS for the treatment of non-syphilis indications, there are no suitable alternatives for the treatment of syphilis. The PBAC advised the delisting of this product may result in an unmet clinical need. The Department sought to retain the product in line with this advice, however the sponsor indicated retention was unviable due to technical manufacturing problems and wished to proceed with the delisting.



Vanessa McMahon
Director, PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
18 April 2024